Emilio A. Emini, Ph.D. is the Director of the Tuberculosis and HIV Program at the Bill & Melinda Gates Foundation.  He is also a Board member of the Gates Medical Research Institute.  Emilio joined the foundation in 2015 following a greater than 30-year career in the biopharmaceutical industry during which he held multiple senior positions in anti-infectives and vaccines R&D.  At the Merck Research Laboratories, from 1983 to 2004, Emilio led the biological research that developed the first of the highly active antiretroviral therapies for HIV, and he led multiple teams involved in vaccine development programs including the recombinant hepatitis B, inactivated hepatitis A, the human papillomavirus, varicella, and rotavirus vaccine programs.  Following a two-year leave from the industry at the International AIDS Vaccine Initiative, Emilio joined Wyeth/Pfizer Inc. as the Senior Vice President of Vaccine R&D where he led the development of the Prevenar 13 vaccine for prevention of pneumococcal disease.  In addition to his present role at the foundation, Emilio serves as an advisor to the COVID vaccine programs of the U.S. Department of Health and Human Services.